SONNET BIOTHERAPEUTICS HOLDINGS, INC.
BURG evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BURG—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
son-080 (Phase 2)
Next Catalyst
—
Financial data as of Sep 30, 2025.
Tracking 2 pipeline candidates · 2 clinical trials for SONNET BIOTHERAPEUTICS HOLDINGS, INC..
Run SONNET BIOTHERAPEUTICS HOLDINGS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SONNET BIOTHERAPEUTICS HOLDINGS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.38
Lead: Phase 1/Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is SONNET BIOTHERAPEUTICS HOLDINGS, INC.'s lead drug candidate?
SONNET BIOTHERAPEUTICS HOLDINGS, INC.'s most advanced tracked candidate is son-080 (Phase 2) for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
Who is the CEO of SONNET BIOTHERAPEUTICS HOLDINGS, INC.?
Raghu Rao is the chief executive officer of SONNET BIOTHERAPEUTICS HOLDINGS, INC. (BURG).
What therapeutic areas does SONNET BIOTHERAPEUTICS HOLDINGS, INC. focus on?
SONNET BIOTHERAPEUTICS HOLDINGS, INC. develops therapies across Oncology, Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.